Litcius/Paper detail

Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study

Anbang Wang, Ming Chen, Duocai Li, Jiazi Shi, Wenbin Tang, Zongqin Zhang, Shancheng Ren

2024Clinical Genitourinary Cancer12 citationsDOI

Topics & Concepts

MedicineBladder cancerOncologyInternal medicineUrologyCancerBladder and Urothelial Cancer TreatmentsTissue Engineering and Regenerative MedicineUrinary and Genital Oncology Studies
Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study | Litcius